10/4/2012

Two late-stage studies found that adding Johnson & Johnson's diabetes drug candidate canagliflozin to standard or existing therapy reduced blood glucose for the most vulnerable patients, including those at high risk of heart disease and older people who struggle to control blood glucose.

Related Summaries